Lipid metabolic reprogramming in colorectal cancer: Insights to mechanisms and therapeutics

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Oct 15, 2025; 17(10): 109398
Published online Oct 15, 2025. doi: 10.4251/wjgo.v17.i10.109398

Table 3 Clinical trials associated with lipid metabolism for colorectal cancer therapy

Target	Treatment	Phase	Clinical trials
COX	Sulindac combined with erlotinib	Phase II	NCT01187901
COX	Asprin combined with anti-PD-1 Ab	Phase II	NCT03638297
Inhibit autophagy	Hydroxychloroquine and autophinib	Phase II	NCT02316340
Ferroptosis	Neratinib	Clinical	NCT03457896
COX	Celecoxib combined with irinotecan	Phase I	NCT00084721

COX: Cyclooxygenases; PD-1: Programmed cell death protein 1; NCT: National clinical trials.

Citation: Wang CD, Zhang BX, Song J. Lipid metabolic reprogramming in colorectal cancer: Insights to mechanisms and therapeutics. World J Gastrointest Oncol 2025; 17(10): 109398
URL: https://www.wjgnet.com/1948-5204/full/v17/i10/109398.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i10.109398

Wang CD, Zhang BX, Song J. Lipid metabolic reprogramming in colorectal cancer: Insights to mechanisms and therapeutics. World J Gastrointest Oncol 2025; 17(10): 109398 [PMID: 41114120 DOI: 10.4251/wjgo.v17.i10.109398]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.